Introduction
The term 'polymyositis' is generally used to refer to the idiopathic inflammatory myopathies, which are the most commonly encountered acquired myopathies in clinical practice'. Patients with polymyositis may present to physicians in a variety of disciplines depending on the predominant symptom; weakness, skin rash, myalgia, or rarely dysphagia or features of cardiorespiratory involvement. Treatment involves the use of steroids and sometimes other immunosuppressive drugs, but the efficacy of steroids has never been demonstrated in a controlled clinical trial 2 • 3 and there are no clear guidelines as to the optimal dose or duration of therapy. Premature withdrawal can result in severe exacerbation of symptoms while prolonged use of steroids in large doses may result in severe side-effects, including progressive weakness.
We have conducted a prospective study of nine patients with polymyositis or dermatomyositis (PMIDM) in order to compare the value of some commonly used methods of monitoring progress during treatment, such as bed-side manual muscle strength testing (MMT) and measurements of erythrocyte sedimentation rate (ESR) and serum creatine kinase (CK), with functional (dynamic) strength assessments and measurements of serum myoglobin (Mb), The possibility that persistent or recurrent weakness during treatment might be due to the development of steroid myopathy is often considered, and the histological changes in muscle during steroid treatment are poorly documented. Seven of our patients therefore underwent serial needle muscle biopsies during the first year of treatment, and the histological changes were studied in relation to the clinical and biochemical findings, and with regard to evidence of steroidinduced muscle damage.
Patients and methods
Nine consecutive patients with PMlDM were recruited to the study. All had histological changes typical of PMlDM on muscle biopsy. Most were under the care of general physicians, rheumatologists or dermatologists who remained primarily responsible for treatment. The patients were also followed independently in the Adult Neuromuscular Diseases Clinic at the Regional Neurological Centre at approximately one to twomonthly intervals for one year and then annually for up to five years.
There were eight females and one male and an age range of 17-68 years (mean 42.6, SD 13.6). Clinically, four patients had DM while the others had PM, usually associated with clinical or serological evidence of other autoimmune diseases (overlap syndrome). No patient had malignancy at the time of presentation or during follow-up. The clinical details are summarized in Table 1 .
Treatment regimens
Treatment varied according to the inclinations of the referring physicians but all patients received an initial high-dose steroid regimen (40-60 mg prednisolone daily or equivalent), followed by an alternate-day treatment after a few weeks. The steroid dose was then reduced by about 10 mg per month, depending on the physicians' clinical assessments, until a maintenance dose of 5-10 mg on alternate days was achieved. This was maintained over the period of observation in most cases, although in three patients it proved possible to withdraw steroid treatment completely. Six of the patients also received azathioprine (Table 1) . e Routine screening included antibodies to nuclear antigens (including extractable nuclear antigens), mitochondria, thyroid cytoplasm and microsomes, smooth muscle, parietal cells, rheumatoid factor PM, polymyositis; MCTD, Mixed connective tissue disease; -, Azathioprine who was unaware of the nature and duration of the patients' treatments.
Clinical assessments
Static manual muscle tests (MMT) were performed on 18 proximal muscle groups prior to treatment and on each subsequent clinic visit. Gradings for each muscle group (on a modified MRC scale) were converted to an analogue score and then summed to give a total score, which was then expressed as a percentage of the maximum possible score", Functional muscle tests (FMT) of the upper limbs were performed by asking patients to execute biceps curls and full arm abductions using small bar-bell weights, while FMT of the lower limbs required the patients to perform full squats. Subjects were urged to carry out as many repetitions as possible for up to one minute, at a steady rhythm. The muscular effort produced, expressed in kilopond-meter minutes (the product of the weight lifted (taken as the body weight for the squats test), the number of repetitions and the fraction of one minute that the patient could continue exercising) was calculated'', These functional tests were also carried out by 30 normal volunteers, 20 women and 10 men, matched as far as possible for age, sex and body-size with our patients. Patients' FMT scores were then expressed as a percentage of the mean value for their appropriate control groups.
Histological assessments
The clinical diagnosis of polymyositis was initially confirmed by open muscle biopsy, usually from the vastus lateralis. Repeat needle biopsies from the same muscle were performed on seven of the patients approximately one month, three months, six months and one year after starting treatment. Cryostat sections were stained with haematoxylin and eosin for histological examination and myofibrillar ATPase activity was demonstrated at pH 9.4 and after preincubation at pH 4.6 and 4.3 for fibre typing". The slides were coded and later scored by a single observer (PH), who was 'blind' to the clinical state and treatment of the patient.
Five groups of pathological changes were defined: inflammatory responses; necrobiotic changes (necrosis, phagocytosis); regenerative activity (basophilic fibres, increases in central nuclei and proportions oftype 2c fibres); fibre atrophy; and 'other changes' including architectural abnormalities in individual fibres on histochemistry, such as loss of ATPase activity. The sum of the inflammatory and necrobiotic scores was termed the 'disease activity score', and the sum of the scores from all five groups the 'total biopsy score'.
The histochemical sections were also examined by an independent observer using a microscope linked to a Kontron Videoplan computer system, in order to determine the proportions of the main fibre types (types 1, 2a, 2b and 2cf, the diameters of individual fibres, and thus the extent of fibre atrophy, hypertrophy" and specific type 2 atrophy, a feature of steroid myopathy",
Laboratory investigations
Measurements of ESR, serum creatine kinase (CK)lO and myoglobin!' were performed at each clinic visit.
Results

Clinical assessments
Although the treatment regimens were broadly similar, responses to treatment varied. Three patients (SG, MM and AR) showed a rapid and sustained response with a marked improvement in muscle testing scores and biopsy appearances, and a rapid fall in serum enzyme and myoglobin levels. All three were able to discontinue immunosuppressive treatment within two years and have remained asymptomatic.
Five patients (SD, EF, VH, AS and AT) also responded well but two patients (EF and AS) relapsed during steroid withdrawal. In both cases, clinical relapse was heralded by a rise in serum enzyme and myoglobin levels, associated with recurrence of weakness, although this was most evident on functional rather than static muscle testing (Figure 1) . Relapses responded to a temporary increase in steroid dose but in all five cases, subsequent attempts to discontinue treatment proved unsuccessful and this group of patients remains dependent on immunosuppressive drugs.
The remaining patient (BP) also showed a good initial response to treatment but her subsequent course was marred by severe relapses which were difficult to control. This case has been reported in II II detail elsewhere'S, but briefly, treatment was discontinued after 20 months when the patient had been asymptomatic for several weeks and had normal serum enzyme and myoglobin levels. She presented five mon L:1S later with a severe exacerbation of myositis and was also found to have clinical and serological evidence of myasthenia gravis. Treatment with steroids and azathioprine alone now failed to improve her condition, but following thymectomy she responded rapidly once more. This improvement was maintained during subsequent steroid dose reduction but attempts to withdraw steroids resulted in relapse on two further occasions, and she has since required maintenance immunosuppressive therapy. ...
.,
'" a: Table 2 gives the scores for inflammatory and necrobiotic changes, and the total biopsy scores during treatment, as determined by qualitative assessment of the coded biopsy sections. No biopsy showed inflammatory changes or necrosis after six months of treatment. In contrast, total biopsy scores remained abnormal to the end of the period of observation in all patients, mainly due to the presence of excess 2c (undifferentiated) fibres, fibre atrophy, and occasionally an excess of fibres with central nuclei. This subjective impression was confirmed by the quantitative study ( Figure 3 ). In most cases there was a reduction in the proportion of type 2 fibres on the initial diagnostic biopsy,with a compensatory increase in the proportions of type 1 and 2c fibres. Atrophy of type 1 or type 2 fibres (and in one patient (AR) both fibre types) was present on the initial biopsy in all but one patient (EF). In contrast, only one patient (SG) developed a specific type 2 atrophy during treatment. There was no correlation between the development of type 2 atrophy and the dose or duration of steroid therapy and much of the apparent type 2 atrophy observed in the qualitative assessments proved to be due to the presence of increased numbers of small 2c fibres.
Histological assessments
Laboratory investigations
The sedimentation rate was increased in six of the patients at the time of diagnosis and returned to normal after three months in all but two; in one (AT) it remained abnormal although the patient became asymptomatic and was able to discontinue treatment. Figure 4 compares the changes in serum CK and myoglobin levels. CK levels fell to normal over the first three months of treatment in all but one patient (BP). Myoglobin levels fell more slowly and remained abnormal in half the cases at three months. We were unable to demonstrate any statistical correlations between the muscle strength assessments and any of the laboratory investigations or muscle biopsy characteristics for the PMfDM patients as a group. However, as Figure 1 illustrates, relapse during steroid withdrawal in individual patients was preceded or accompanied by rises in serum enzyme or myoglobin levels followed by a significant fall in FMT scores, while static MMT results remained relatively unaffected. 
Discussion
There is no clear evidence that steroids and immunosuppressive drugs significantly improve the overall outcome in patients with polymyositie-P but few clinicians would deny that they are usually of benefit in the early management of the condition. Symptoms of weakness and myalgia which may have been present for months are usually controlled within a few days, and premature dose reduction frequently leads to relapse'P, Some cases of even severe polymyositis undoubtedly resolve spontaneously and others respond poorly to immunosuppressive treatment's", but at present we have no way of distinguishing such patients at the time of presentation from those who would benefit from treatment. is, therefore, not whether steroids are of value in this condition, but at what dose and for how long they should be given. Available evidence supports the use of high-dosedaily steroids (1 mg/kg prednisolone daily, or equivalent) at the outset, as used in the present study. In a recent retrospective survey of 100 patients treated with steroids, with or without other immunosuppressive drugs, Henriksson and Sandstedt'" reported that half improved (87% having little or no disability after a median follow-up period of 43 months), while half were resistant to therapy. The dose of steroid did not materially influence outcome in the treatment responsive group, but the rate of improvement showed a positive correlation with the average steroid dose over the first three months of treatment. Edwards and his colleagues however-", have emphasized that the potent catabolic effects of steroids may lead to progressive weakness. In previous reports from this and other centres'", the incidence of steroid-induced side-effects with such a regimen was low, around 5-10%, but some authorities have reported much higher figures-and in Henriksson and Sandstedt's study14 almost half the patients developed steroidrelated complications. In the present study, one
hospital, became cushingoid and developed osteoporosis and multiple vertebral fractures. Another (AT) also received 2 mg/kg daily for several weeks and experienced anorexia, alopecia, oedema, weight loss and progressive weakness, despite improvement in her serum enzyme levels and biopsy characteristics. These symptoms resolved as the dose was reduced and neither patient developed histological features of steroid myopathy.
Decisions regardmg the rate of steroid dose reduction and eventual withdrawal are largely empirical but are often influenced by serial observations of static muscle strength", However, our data suggest that such routine clinical assessments are insensitive and sometimes misleading. For example, MMT scores declined only slightly in the two patients who relapsed during steroid withdrawal, while functional strength measurements showed a much greater deterioration (Figure 1) . Overall, FMT scores improved more slowly than MMT scores during treatment (Figure 2 ), and this may imply that routine bed-side strength assessments over-estimate the rate of recovery, particularly since the serial biopsy data indicate that the muscle architecture remains abnormal for many months after static strength recovers ( Figure 3) .
Serum CK levels are also frequently used as a guide to treatment response, but again are not always reliable. Raised serum levels of muscle enzymes are well documented in myositis and changes in enzyme levels during treatment have occasionally been followed prospectively'<"', Serum CK levels are a reasonably sensitive index of disease activity on presentation'", but not necessarily during steroid therapy', Henriksson and Sandstedt-? reported that CK levels returned to normal more quickly than serum lactate dehydrogenase, aspartate and alanine aminotransferases, and a normal CK level does not necessarily imply clinical or histological remission; similarly, occasional patients show clinical improvement despite persistently raised levels. In the present study, serum myoglobin returned to normal more slowly than CK (Figure 4 ) and in the two patients who relapsed myoglobin concentrations, unlike CK levels, had failed to return to normal at the time of deterioration. Myoglobin (Mb) is a muscle-specific protein of much lower molecular weight than CK and might be expected to be a more sensitive index of muscle damage!'. Some studies have reported raised levels in more than 90% of cases of myositis at diagnosis using radioimmunoassay, and Mb levels appear to be less affected by steroid treatment than CK17.18. Mb levels may also be raised while CK is normal and a correlation between changes in clincial state and myoglobin levels during treatment in individual cases has been reported's. A battery of serum enzymes and myoglobin measurements might therefore be of greater use in monitoring treatment responses in myositis than serum CK alone.
Measurements of ESR did not contribute useful information in this study. De Vere and Bradley'" found that the ESR was raised in about half of their 108 patients at diagnosis and could remain elevated throughout the course of the disease, irrespective of changes in other indices or clinical state. ESR measurements are thus of limited value in monitoring treatment response.
Inflammatory and necrobiotic changes on diagnostic biopsy resolved within six months of starting treatment. In a prospective study, Bunch et al. 19 found that 10 of 16 patients who underwent re-biopsy after three months of therapy had mild persisting inflammatory and necrobiotic changes but again, no correlation between biopsy appearances and changes in strength or enzyme levels was found. In contrast, in a retrospective study Schwartz et al. 20 found that 7 of 11 patients who had undergone repeat biopsy because of poor response to immunosuppressants had evidence of active myositis up to 20 months after starting treatment. Some of these had normal CK levels. Both these groups found significant 'type 2 atrophy' on biopsies during treatment which was attributed to the effects of steroids, but neither commented on the frequency of small type 2c fibres which comprised a significant proportion of the type 2 populations in the present study. These probably represent partially differentiated and perhaps recently regenerated fibres". Furthermore, type 2 atrophy can be seen on diagnostic biopsy in some cases 7 ,19,20 , as in the present study. Our investigation shows that specific atrophy of differentiated type 2 fibres, indicative of steroid myopathyl-", is not a common feature of polymyositis during treatment. Repeat muscle biopsy may thus be of value in differentiating weakness due to active myositis from steroid myopathy but does not appear to be useful in the routine assessment of treatment response.
In-summary, clinical, biochemical and histological studies may each contribute to the assessment of responses to treatment in individual cases but it is difficult to extrapolate such results to polymyositis patients as a group. There would seem to beadvantages in the use of quantitative, and particularly functional, strength assessments in the management of PMIDM patients. Several groups have described the use of dynamometers and other strength-measuring devices to this end 15 ,16 , but simple techniques, such as the time taken to stand 10 times from a standard chair, have been shown to provide a reliable guide to changes in lower limb strength during treatment-", Wider availability of more recently described techniques such as measurements of anti-myoglobin'", and antimyosin-" antibody titres, which were reported to vary in relation to clinical status, may further improve the monitoring of clinical progress. However, all these methods report essentially on the state of the target organ, skeletal muscle, rather than the underlying immunological disturbances and further progress awaits the clarification of factors influencing the pathogenesis and prognosis in this group of disorders.
